CCCC Stock — C4 Therapeutics Inc.: Cash, EV, Pipeline

Share price

$3.39

Market cap

$417.1M

Cash

$253.7M

Enterprise value

$163.4M

Balance sheet

Cash	$253.7M
Debt	$0.0M
Net cash	$253.7M
Enterprise value	$163.4M
Basic shares	122.9M shares
Fully diluted shares	269.5M shares
Fully diluted market cap	$913.5M
Cash per share	$2.06

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading CCCC daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Nov 11 - Dec 23	cemsidomide	Phase 1	Multiple Myeloma; Lymphoma, Non-Hodgkin's	—
Jan 12 - Feb 23	Cemsidomide	Phase 1	Multiple Myeloma (MM)	—
Apr 12 - May 24	Cemsidomide	Phase 2	Multiple Myeloma; Relapsed/Refractory Multiple Myeloma	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

Cemsidomide

Phase 1 · Active Modality: molecular glue degrader

Target IKZF1, IKZF3

Partnerships Pfizer: clinical trial collaboration & supply agreement (Sep 2025); Pfizer supplies elranatamab at no cost; company sponsors and conducts the trial

Indications

Multiple myeloma (Phase 1)

Status note IKZF1/3 degrader (MonoDAC). Most advanced product candidate per filing. Ongoing/planned Phase 1b trial in combination with dexamethasone and elranatamab in second-line or later multiple myeloma.

CFT8919

Phase 1 · Active Modality: protein degrader

Target EGFR (L858R mutant)

Partnerships Betta Pharma: exclusive Greater China license (May 2023); $10M upfront, up to $357M milestones; C4 retains rest-of-world rights

Indications

not disclosed (Phase 1)

Status note Allosteric, mutant-selective BiDAC degrader of EGFR L858R (target/modality per 10-K fallback). Phase 1 trial referenced in primary; Betta Pharma conducts clinical development in Greater China, C4 retains ex-Greater China rights.

Per-asset detail extracted from the 10-Q filed 2026-08-11. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Cemsidomide
Lead indication	Multiple Myeloma
Lead phase	Phase 2
Active trials	3

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07284758	Phase 2	Recruiting	Sponsor	C4 Therapeutics, Inc.	—	Multiple Myeloma; Relapsed/Refractory Multiple Myeloma	—
NCT04756726	Phase 1	Active, not recruiting	Sponsor	C4 Therapeutics, Inc.	—	Multiple Myeloma; Lymphoma, Non-Hodgkin's	—
NCT07280013	Phase 1	Recruiting	Sponsor	C4 Therapeutics, Inc.	—	Multiple Myeloma (MM)	—

Sponsor-matched active trials from ClinicalTrials.gov (3 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 3 active trials for C4 Therapeutics, Inc. on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
Ikarian Capital	2,433,000	+2,433,000	1.86%	2026-08-14
ADAR1 Capital Management	291,957	+248,957	0.06%	2026-08-14
OrbiMed Advisors	0	-856,353	0.00%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

CCCC — C4 Therapeutics Inc.